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Anemia management and chronic renal failure progression.
Analysis of the biologic effects of erythropoietin and patho-
physiology of chronic kidney diseases (CKD) suggests that
treatment with erythropoiesis-stimulating agents (ESA) could
slow the progression of CKD. By decreasing hypoxia and ox-
idative stress, it could prevent the development of interstitial
fibrosis and the destruction of tubular cells. It could have di-
rect protective effects on tubular cells through its antiapoptotic
properties. It could help maintain the integrity of the intersti-
tial capillary network through its effects on endothelial cells.
Thus, suggesting that correcting anemia with ESA could slow
the progression of CKD is biologically plausible.
In patients with CKD, three small prospective studies and
a retrospective study have suggested that treatment with ESA
may have protective effects. Post-hoc analysis of the Reduction
in Endpoints in Noninsulin-dependent Diabetes Mellitus with
the Angiotensin II Antagonist Losartan study has also shown
that anemia was an independent risk factor for progression of
nephropathy in patients with type 2 diabetes. In addition, a large
clinical trial, which had to be stopped prematurely because of la-
beling change for subcutaneous administration of epoetin alfa,
suggests that complete normalization of hemoglobin levels is
safe in CKD patients not on dialysis and without severe cardio-
vascular disease. Thus, it seems reasonable to advocate starting
a large randomized, prospective study to determine if normal-
ization of hemoglobin concentration can effectively slow the
progression of CKD.
Renal failure results in considerable increase of car-
diovascular morbidity and mortality, and is associated
with decreased quality of life and heavy costs from re-
nal replacement therapies. Furthermore, in the 1990s,
the incidence of end-stage renal disease has been relent-
lessly increasing at an annual rate of about 6% to 8% in
most European countries and even more rapidly in the
United States [1]. Slowing the progression of renal failure
thus appears to be a major therapeutic challenge. Besides
treatment of the underlying disease, the main therapeutic
tools that are available are optimal control of blood pres-
sure, use of angiotensin-converting enzyme inhibitors or
angiotensin II receptor blockers, and strict glycemic con-
trol in patients with diabetes mellitus [1]. The efficacy of
these therapies is limited, however, and there is a clear
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need for additional treatments. Among the therapeutic
interventions that could slow the progression of chronic
kidney disease (CKD) is correction of anemia through ad-
ministration of erythropoiesis-stimulating agents (ESA).
BIOLOGIC EFFECTS OF TREATMENT WITH ESA
The most obvious benefit of treatment with ESA is
an increase in red blood cell concentration, which is re-
sponsible for increased oxygen delivery to tissues and re-
duction of hypoxia. However, administration of ESA has
other effects, including protection against oxidative stress
and apoptosis, and possibly stimulation of angiogenesis.
Erythrocytes represent a major antioxidant compo-
nent of blood [2]. Their antioxidant effects are mediated
through enzymes such as superoxide dismutase, catalase,
and glutathione peroxidase, and through cellular pro-
teins that are devoided of enzymatic activity but can re-
act with reactive oxygen species, such as low-molecular
weight proteins of the erythrocyte membrane, vitamin
E, vitamin C, or coenzyme Q. Furthermore, glutathione
reductase can regenerate reduced glutathione from its
oxidized form, using reduced nicotinamide adenine din-
ucleotide phosphate produced through the pentose phos-
phate pathway.
The ability of erythropoietin to promote survival of
erythroid progenitors via the binding to its receptor has
been established for a long time. However, recent stud-
ies have shown that erythropoietin receptors are also ex-
pressed in a variety of non-hematopoietic cells, such as
neuronal cells, cardiomyocytes, vascular cells, and renal
tubular cells, and that the binding of erythropoietin to
these receptors can have antiapoptotic effects [3]. Protec-
tion against apoptosis appears to be mediated by differ-
ent pathways, including (1) activation of the transcription
of genes encoding antiapoptotic molecules such as Bcl-
xL, XIAP, or c-IAP2; (2) inhibition of the transcription of
genes encoding proapoptotic molecules such as Fas ligand
or Bim; (3) activation of protein kinase B/Akt through
the phosphatidylinositol 3-kinase pathway; and (4) in-
duction of heat shock protein 70 (Fig. 1). In agreement
with these data, acute administration of relatively large
doses of erythropoietin can dramatically decrease the
consequences of experimental injuries of neuronal cells,
S-76
Rossert et al: Anemia and progression of CKD S-77
Fig. 1. Schematic representation of the pathways by which the binding of EPO to its receptor can inhibit apoptosis. Binding of EPO induces: (A)
phosphorylation of the STAT5 transcription factor that will then homodimerize, translocate into the nucleus, and activate target genes encoding
antiapoptotic molecules such as Bcl-XL; (B) phosphorylation of phosphatidylinositol 3-kinase (PI-3 kinase) that, in turn, phosphorylates protein
kinase B (PKB)/Akt, which then phosphorylates (1) proapoptotic molecules such as Bad, caspase 9, or glycogen synthase kinase-3b (GSK-3b),
leading to their inactivation, (2) FOXO transcription factors (FOXO TF), inducing their retention into the cytoplasm, and thus preventing activation
of target genes such as Fas ligand or Bim, (3) I-jB, leading to the activation of the transcription factor nuclear factor-jB; (C) phosphorylation of
I-jB, which allows the release of the transcription factor nuclear factor-jB, its translocation into the nucleus and activation of target genes encoding
antiapoptotic molecules such as XIAP and c-IAP2; and (D) activation of heat shock protein 70 (Hsp70), which binds to and inactivates proapoptotic
molecules such as apoptosis protease activating factor-1 (Apaf-1) and apoptosis-inducing factor (AIF). Reprinted from [3] with permission.
transient or permanent occlusion of a coronary artery, or
renal ischemia-reperfusion injury [3]. For example, pre-
treatment of animals with recombinant human erythro-
poietin at a dose ranging from 300 to 5000 IU/kg can
reduce renal dysfunction and morphologic damage after
transient clamping of renal artery [4–8]. These protective
effects appear to be mostly mediated by a decrease of
apoptotic cell death [4, 6].
Analyses of knock-out mice have shown that the bind-
ing of erythropoietin to its receptors is required for nor-
mal development of the heart and brain [9, 10], but also
for normal angiogenesis [11], demonstrating that phys-
iologic doses of erythropoietin can have proangiogenic
effects. These data are in agreement with in vivo data
obtained with chick embryo chorioallantoic membrane,
and with in vitro experiments performed with cultured
endothelial cells that have outlined the proangiogenic ef-
fects of erythropoietin [12, 13]. Recently, Bahlmann et al
have shown that low doses of darbepoetin alfa, which did
not increase hematocrit levels, had protective effects in
rats undergoing subtotal nephrectomy [14]. Interestingly,
in this model, treatment with ESA prevented the loss of
peritubular capillaries. Because the Akt/protein kinase
B pathway was activated, ESA may act by inhibiting the
apoptosis of endothelial cells.
Experiments performed with neuronal cells have also
shown that the binding of recombinant erythropoietin to
its receptors can protect against oxidative stress [15]. It
activates nuclear factor-jB which, in turn, enhances the
expression of genes encoding proteins such as superoxide
dismutase that have potent antioxidant properties. How-
ever, it is not known whether erythropoietin can have
similar antioxidant properties in other cell types.
BIOLOGIC LINKS BETWEEN TREATMENT
WITH ESA AND PROGRESSION OF CKD
During the course of CKD, nephron destruction is
caused by direct effects of the underlying disease on
glomerular, tubular, or vascular structures, and also two
vicious circles triggered by reduction in nephron number
(Fig. 2). One links nephron loss with glomerulosclerosis
S-78 Rossert et al: Anemia and progression of CKD
Glomerular
injury
Initial insult
Interstitial
fibrosis
Destruction
of capillaries
Hypoxia of
tubular cells
Tubular
dysfunction
Glomerulo-
sclerosis
Glomerular
hypertension
/hypertrophy
Modifications
of cell functions—  Proteinuria
Destruction
of tubular cells
Reduction in
nephron number
Fig. 2. Schematic representation of the
mechanisms responsible for nephron loss in
patients with glomerular disease. An initial
glomerular insult is responsible for alter-
ations of glomerular cell functions, leading
to glomerulosclerosis and thus reduction in
nephron number. Reduced nephron number
induces an increase in glomerular capillary
pressure and/or glomerular volume, which
leads to further glomerular damage. Reduced
nephron number is also associated with tubu-
lar dysfunction. The modifications of tubular
cell functions are responsible for interstitial
fibrosis and destruction of peritubular cap-
illaries, which leads to tubular destruction.
Destruction of interstitial capillaries may also
increase glomerular capillary pressure and
thus enhance glomerular damage. Similarly,
glomerulosclerosis damages glomerular
capillaries and enhances tubular hypoxia.
Proteinuria enhances tubular dysfunction and
thus interstitial fibrosis.
and glomerular destruction. The other links reduction
in nephron number with interstitial fibrosis and tubular
damage.
The glomerular vicious circle has been highlighted by
pioneer work performed in Brenner’s laboratory more
than 20 years ago [16]. Experimental studies performed
in rats undergoing subtotal nephrectomy have shown that
nephron loss increases capillary pressure and flow in the
remaining glomeruli and induces hypertrophy of these
glomeruli which, in turn, leads to podocyte injury, over-
production of extracellular matrix by mesangial cells, and
glomerulosclerosis [16]. Human sequential studies of re-
nal biopsies obtained from few patients who had an im-
portant reduction of their renal mass have also shown
that a decrease in nephron number can be responsible
for the development of glomerulosclerosis [17].
Two series of observations derived from careful anal-
yses of renal biopsies have suggested that reduction in
nephron number is responsible for the development of
interstitial fibrosis, and that the corresponding intersti-
tial lesions play a key role in the progression of CKD.
First, during the course of many renal diseases, there is a
striking correlation between renal function and severity
of interstitial fibrosis [18, 19]. Second, the extent of in-
terstitial fibrosis is the best histologic prognostic marker
of most renal diseases, including glomerular and vascular
diseases [20–23]. As pointed out by Fine and Johnson,
hypoxia probably plays a central role in this process, fa-
voring both the production of extracellular matrix and
nephron loss [24, 25]. In patients with reduced nephron
number, hypoxia of tubular cells is favored by (1) an
increase of oxygen consumption by tubular cells of the
remaining nephrons; (2) a decrease in the number of in-
terstitial capillaries [26]; and (3) an accumulation of extra-
cellular matrix between interstitial capillaries and tubular
cells, which hampers oxygen diffusion. In turn, hypoxia
appears to have at least three consequences. First, it stim-
ulates the production of profibrotic molecules, such as
transforming growth factor-b or endothelin-1, by tubu-
lar cells, as well as the synthesis of extracellular matrix
by these cells [27, 28]. Second, it directly enhances the
production of extracellular matrix by fibroblastic cells
[29]. Third, it ultimately leads to a destruction of tubules,
with formation of so-called “atubular glomeruli.” The
importance of tubular destruction in the progression of
CKD has been highlighted by analysis of various experi-
mental models of CKD as well as by careful analyses of
renal biopsies [30]. For example, after subtotal nephrec-
tomy, progression of renal failure appears to be due much
more to tubular destruction with formation of atubular
glomeruli than to glomerulosclerosis [31]. In patients with
renal failure, increased oxygen consumption by the re-
maining nephrons favors hypoxia, but it also enhances
the production of reactive oxygen species, which could
play a role in progression of CKD. Oxidative stress has
been shown to induce the release of proinflammatory
and profibrotic molecules, such as monocyte chemotactic
protein-1 and transforming growth factor-b1, to directly
enhance the production of extracellular matrix by fibrob-
lastic cells and favor cell death [32–36]. Its role in CKD
progression is supported by experiments showing that,
in vivo, treatment of rats with antioxidants can protect
against the development of interstitial fibrosis, whereas
deprivation of antioxidants has opposite effects [32, 37].
Analysis of the mechanisms of progression of CKD
shows that treatment with ESA could exert protective
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Fig. 3. Schematic representation of the po-
tential links between treatment with ESA and
nephroprotection. Treatment with ESA will
reduce hypoxia and oxidative stress and pos-
sibly have proangiogenic and antiapoptotic ef-
fects. This will lead, in turn, to decreased pro-
duction of extracellular matrix, protection of
interstitial capillary network, and protection
of tubular cells and interstitial cells.
effects at different levels (Fig. 3). It could (1) slow the de-
velopment of interstitial fibrosis as well as the destruction
of tubular cells by decreasing hypoxia and oxidative stress
through correction of anemia; (2) have direct protective
effects on tubular cells; and (3) help maintain the integrity
of the interstitial capillary network. Thus, suggesting that
correcting anemia with ESA could slow the progression
of CKD is biologically plausible.
CLINICAL STUDIES SUGGESTING THAT
TREATMENT WITH ESA MAY SLOW THE
PROGRESSION OF RENAL FAILURE
The fact that correcting anemia does not accelerate the
progression of CKD has been shown by different clinical
studies performed in the early 1990s, and it is not ques-
tioned anymore. Nevertheless, the question of whether
it slows the progression of renal failure remains an open
one. So far, this hypothesis is mostly supported by three
prospective clinical studies including a limited number of
patients [38–40].
The first study, which was published in 1994, included
83 patients with severely impaired renal function [mean
measured glomerular filtration rate (GFR) 10 mL/min]
and severe anemia (mean hematocrit, 26.8%) [38]. Af-
ter a two-month stabilization period, 40 patients were
randomly assigned not to receive epoetin and 43 to re-
ceive epoetin in order for their hematocrit to reach 35%.
The patients were followed up for 48 weeks. No benefi-
cial effect of epoetin could be demonstrated by simply
comparing renal survival or GFR decrease between the
two groups of patients. Nevertheless, when data were an-
alyzed only after the hematocrit levels of the patients
included in the epoetin group had reached the target val-
ues (i.e., after week 16), the rate of GFR decline was
three times slower in the treated group than in the con-
trol group (−0.13 ± 0.35 mL/min/month vs. −0.39 ± 0.65
mL/min/month, P = 0.05).
The second study, which was published in 1997, in-
cluded 73 patients with severe anemia (mean hemat-
ocrit, 27.4%) and renal failure (mean creatinine clear-
ance, 18.2 mL/min) [39]. After an eight-week stabiliza-
tion period, the patients were randomly assigned to re-
ceive or not receive epoetin. Thirty-one patients were
left untreated. Forty-two patients received epoetin to in-
crease their hematocrit to 33% to 35%. Follow-up was
at 36 weeks. During this period, creatinine doubled in
about 52% of patients in the treated group and in more
than 90% of patients in the control group (P < 0.0005).
Furthermore, while 64% of patients in the control group
required dialysis, only 33% of those in the epoetin group
had to start dialysis (P < 0.005).
The third study was published in 2004 [40]. Eighty-eight
patients with nondiabetic nephropathy, proteinuria of
less than 2 g/day, and hemoglobin concentration between
9 g/dL and 11.6 g/dL were randomly allocated to early or
late treatment with ESA. Patients included in the for-
mer group received epoetin to increase their hemoglobin
concentration above 13 g/dL. Those included in the lat-
ter group did not receive epoetin until their hemoglobin
concentration decreased below 9 g/dL. Treatment with
an angiotensin-converting enzyme inhibitor was not per-
mitted during the study. After a median follow-up of 22.5
months, significantly more patients reached a combined
end point of doubling of serum creatinine, end-stage re-
nal disease, or death in the early treatment group (13 vs.
23, P < 0.01). Similarly, significantly less patients reached
a combined end point of end-stage renal disease or death
in the early treatment group (13 vs. 22, P = 0.01).
In addition to these prospective randomized studies,
a retrospective and noncontrolled study also suggested
that treatment with ESA may slow the progression of
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renal failure [41]. In this study, the authors compared 20
patients with CKD who were treated with epoetin with 43
patients who had a similar degree of renal failure but who
were less anemic and, thus, did not receive epoetin. The
rate of decline of creatinine clearance did not change over
time in the control group, whereas in the treated group, it
was significantly slower after epoetin treatment had been
started (−0.36 ± 0.16 mL/min/1.73 m2/month vs. −0.26
± 0.15 mL/min/1.73 m2/month, P < 0.05). Although this
study has many limitations, it suggests that treatment with
ESA could have protective effects that are not mediated
by correction of anemia.
A post-hoc analysis of the Reduction in Endpoints in
Noninsulin-dependent Diabetes Mellitus with the An-
giotensin II Antagonist Losartan study also supports the
possibility that correction of anemia may slow the pro-
gression of CKD [42]. A total of 1513 type 2 diabetes
patients with nephropathy were included in this double-
blind, randomized trial designed to test the renoprotec-
tive properties of losartan. Multivariate analysis showed
that, in this population, anemia was an independent risk
factor of progression, together with the levels of serum
creatinine, proteinuria, and serum albumin.
In 2001, the Effect of Early Correction of Anaemia on
the Progression of Chronic Kidney Disease study was ini-
tiated to define the effects of complete correction of ane-
mia with epoetin alfa on progression of CKD. The main
inclusion criteria were an estimated GFR between 60 and
25 mL/min, and hemoglobin levels below 13 g/dL for men
and 12.5 g/dL for women. Patients included in this study
were randomly assigned to early treatment with epoetin
alfa to achieve high hemoglobin targets (13–15 g/dL), or
to conventional treatment with no administration of epo-
etin as long as hemoglobin levels were above 11 g/dL.
Unfortunately, the study was terminated early because
of labeling change for subcutaneous administration of
epoetin alfa. Only 391 patients were included, and mean
follow-up was only 7.4 months in the high hemoglobin
group and 8.3 months in the low hemoglobin group. Mea-
sured GFR decline was numerically, but not statistically,
significantly lower in the high hemoglobin group (0.058
vs. 0.081 mL/min/1.73m2/month). Importantly, adverse
events rates were similar between the two groups, and
neither epoetin dosage nor hemoglobin level was associ-
ated with cardiovascular adverse events or death.
CONCLUSION
The hypothesis that correction of anemia with ESA
may slow the progression of renal failure is biologically
plausible, and preliminary results issued from few clini-
cal studies suggest that it is worth being tested in a large
prospective study. In our opinion, such a study should in-
clude patients with moderate anemia, treated according
to current guidelines, and randomly assigned to receive
treatment with ESA to normalize their hemoglobin lev-
els. The Effect of Early Correction of Anaemia on the
Progression of Chronic Kidney Disease study has shown
that such a study is feasible.
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